Get the Stockscreener App
11.98
4.92%
-0.62
After Hours:
11.59
-0.39
-3.26%
Nextcure Inc stock is traded at $11.98, with a volume of 19,826.
It is down -4.92% in the last 24 hours and up +105.14% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$12.60
Open:
$11.98
24h Volume:
19,826
Relative Volume:
0.54
Market Cap:
$32.06M
Revenue:
-
Net Income/Loss:
$-58.52M
P/E Ratio:
-5.7321
EPS:
-2.09
Net Cash Flow:
$-45.03M
1W Performance:
+29.23%
1M Performance:
+105.14%
6M Performance:
+2,607%
1Y Performance:
+800.75%
1-Day Range:
$11.18
$12.53
1-Week Range:
$9.51
$13.15
52-Week Range:
$0.224
$13.17
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
11.98 | 33.72M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
What technical models suggest about NextCure Inc.’s comebackQuarterly Market Review & Momentum Based Trading Signals - newser.com
How sentiment analysis helps forecast NextCure Inc.Weekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Is NextCure Inc. stock reversal real or fakeMarket Growth Summary & Precise Swing Trade Alerts - newser.com
Key metrics from NextCure Inc.’s quarterly dataGlobal Markets & Detailed Earnings Play Alerts - newser.com
NextCure Inc. recovery potential after sell offInsider Selling & Daily Chart Pattern Signal Reports - newser.com
How institutional ownership impacts NextCure Inc. stockWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Why analysts remain bullish on NextCure Inc. stockJuly 2025 Update & Fast Gain Stock Trading Tips - newser.com
Why NextCure Inc. stock is favored by top institutionsJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - newser.com
What MACD signals say about NextCure Inc.Earnings Trend Report & High Accuracy Trade Alerts - newser.com
Comparing NextCure Inc. in custom built stock radarsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
How to integrate NextCure Inc. into portfolio analysis tools2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com
Predicting NextCure Inc. trend using moving averagesTrade Risk Summary & Technical Buy Zone Confirmations - newser.com
How NextCure Inc. stock reacts to inflationary pressures2025 Market Sentiment & Fast Moving Stock Trade Plans - newser.com
Has NextCure Inc. found a price floorWatch List & Trade Opportunity Analysis Reports - newser.com
NextCure Inc Stock Analysis and ForecastSector Rotation Strategies & These 3 Stocks Could Change Your Portfolio - earlytimes.in
Evaluating NextCure Inc. with trendline analysisPortfolio Update Report & Expert Approved Momentum Trade Ideas - newser.com
Best data tools to analyze NextCure Inc. stockMarket Movement Recap & Real-Time Buy Zone Alerts - newser.com
Using Python tools to backtest NextCure Inc. strategies2025 Top Gainers & Daily Profit Maximizing Tips - newser.com
Visual analytics tools that track NextCure Inc. performance2025 Historical Comparison & Stepwise Swing Trade Plans - newser.com
NextCure, Inc. (NXTC) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):